Sign In
Buy REPL
$9.98
+1.11 (+12.51%)
At Close: Jun 03, 2026
Anebulo Pharmaceuticals (NASDAQ:ANEB) & Replimune Group (NASDAQ:REPL) Critical Comparison
02:08am, Thursday, 12'th Mar 2026
Replimune Group (NASDAQ: REPL - Get Free Report) and Anebulo Pharmaceuticals (NASDAQ: ANEB - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare th
Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect?
10:56am, Tuesday, 03'rd Mar 2026
The mean of analysts' price targets for Replimune Group (REPL) points to a 79.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among
Replimune to Present at Two Upcoming Investor Conferences
08:00am, Monday, 02'nd Mar 2026
WOBURN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today anno
Wall Street Analysts Predict a 65.72% Upside in Replimune Group (REPL): Here's What You Should Know
10:55am, Thursday, 12'th Feb 2026
The consensus price target hints at a 65.7% upside potential for Replimune Group (REPL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings e
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
08:00am, Tuesday, 03'rd Feb 2026
WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today annou
SG Americas Securities LLC Increases Stake in Replimune Group, Inc. $REPL
05:22am, Monday, 26'th Jan 2026
SG Americas Securities LLC grew its position in Replimune Group, Inc. (NASDAQ: REPL) by 868.0% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 98,731 sha
Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
07:15pm, Wednesday, 14'th Jan 2026
Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months
03:46pm, Wednesday, 31'st Dec 2025
REPL shares soar 131.1% over the past three months after the FDA accepts its resubmitted BLA for the RP1/Opdivo combo in advanced melanoma.
Squarepoint Ops LLC Grows Stock Position in Replimune Group, Inc. $REPL
05:20am, Wednesday, 24'th Dec 2025
Squarepoint Ops LLC lifted its position in Replimune Group, Inc. (NASDAQ: REPL) by 394.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commi
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
08:00am, Thursday, 18'th Dec 2025
WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today annou
Replimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of “Moderate Buy” by Brokerages
04:19am, Saturday, 22'nd Nov 2025
Replimune Group, Inc. (NASDAQ: REPL - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eleven ratings firms that are covering the company, MarketBeat reports. Two analys
Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failure Oral presentation of b
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
08:00am, Thursday, 06'th Nov 2025
WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today annou
KLP Kapitalforvaltning AS Has $70,000 Stock Holdings in Replimune Group, Inc. $REPL
03:08am, Wednesday, 22'nd Oct 2025
KLP Kapitalforvaltning AS reduced its position in Replimune Group, Inc. (NASDAQ: REPL) by 39.5% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 7,500 shares
Why Replimune Stock Was Soaring Today
04:10pm, Monday, 20'th Oct 2025
Biotech stocks can be volatile, a tendency that was very much in Replimune Group's (REPL 100.00%) favor on Monday. The biotech's stock had more than doubled in late-session action, thanks to some very
